Skip to main content
Top
Published in: European Journal of Clinical Microbiology & Infectious Diseases 3/2005

01-03-2005 | Article

Resistance of multidrug-resistant strains of Mycobacterium tuberculosis from the Archangel oblast, Russia, to second-line anti-tuberculosis drugs

Authors: O. S. Toungoussova, A. O. Mariandyshev, G. Bjune, D. A. Caugant, P. Sandven

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 3/2005

Login to get access

Abstract

Multidrug-resistant tuberculosis has become common all over the world, necessitating the inclusion of second-line drugs in treatment regimens. In the present study, the susceptibility of a selection of multidrug-resistant strains of Mycobacterium tuberculosis isolated in the Archangel oblast, Russia, to second-line anti-tuberculosis drugs was analysed. Susceptibility testing of 77 Mycobacterium tuberculosis strains was performed by the Bactec method using the following recommended drug concentrations: capreomycin 1.25 μg/ml; ethionamide 1.25 μg/ml; kanamycin 5 μg/ml; and ofloxacin 2 μg/ml. The majority of strains (92.2%) were resistant to ethionamide. High rates of drug resistance were also found for capreomycin (42.9%) and kanamycin (41.6%), while nearly all strains (98.7%) were susceptible to ofloxacin. The high rates of resistance to ethionamide, capreomycin, and kanamycin show the real burden of drug resistance in the region and pose a serious problem for the treatment of patients with multidrug-resistant tuberculosis.
Literature
1.
go back to reference World Health Organization (2003) Guidelines for surveillance of drug resistance in tuberculosis. Document no. WHO/TB/2003.320–WHO/CDS/CSR/RMD/2003.3. WHO, Geneva, p71 World Health Organization (2003) Guidelines for surveillance of drug resistance in tuberculosis. Document no. WHO/TB/2003.320–WHO/CDS/CSR/RMD/2003.3. WHO, Geneva, p71
2.
go back to reference World Health Organization/International Union Against Tuberculosis and Lung Disease (2004) Anti-tuberculosis drug resistance in the world. Report no 3. WHO, Geneva, p129 World Health Organization/International Union Against Tuberculosis and Lung Disease (2004) Anti-tuberculosis drug resistance in the world. Report no 3. WHO, Geneva, p129
3.
go back to reference World Health Organization (1996) TB: groups at risk. WHO report on the tuberculosis epidemic. Document no. WHO/TB/96.198. WHO, Geneva, p28 World Health Organization (1996) TB: groups at risk. WHO report on the tuberculosis epidemic. Document no. WHO/TB/96.198. WHO, Geneva, p28
4.
go back to reference Dye C, Espinal MA, Watt CJ, Mbiaga C, Williams BG (2002) Worldwide incidence of multidrug-resistant tuberculosis. J Infect Dis 185:1197–1202 Dye C, Espinal MA, Watt CJ, Mbiaga C, Williams BG (2002) Worldwide incidence of multidrug-resistant tuberculosis. J Infect Dis 185:1197–1202
5.
go back to reference Toungoussova OS, Mariandyshev AO, Bjune G, Sandven P, Caugant DA (2003) Molecular epidemiology and drug resistance of Mycobacterium tuberculosis isolates in the Archangel prison, Russia: predominance of the W-Beijing clone family. Clin Infect Dis 37:665–672 Toungoussova OS, Mariandyshev AO, Bjune G, Sandven P, Caugant DA (2003) Molecular epidemiology and drug resistance of Mycobacterium tuberculosis isolates in the Archangel prison, Russia: predominance of the W-Beijing clone family. Clin Infect Dis 37:665–672
6.
go back to reference Laing RO, McGoldrick KM (2000) Tuberculosis drug issues: prices, fixed-dose combination products and second-line drugs. Int J Tuberc Lung Dis 4:5194–5207 Laing RO, McGoldrick KM (2000) Tuberculosis drug issues: prices, fixed-dose combination products and second-line drugs. Int J Tuberc Lung Dis 4:5194–5207
7.
go back to reference World Health Organization (2003) Treatment of tuberculosis: guidelines for national programmes. Document no. WHO/CDS/TB/2003.312. WHO, Geneva, p112 World Health Organization (2003) Treatment of tuberculosis: guidelines for national programmes. Document no. WHO/CDS/TB/2003.312. WHO, Geneva, p112
8.
go back to reference Sterling TR, Lehmann HP, Frieden TR (2003) Impact of DOTS compared with DOTS-Plus on multidrug resistant tuberculosis and tuberculosis deaths: decision analysis. BMJ 326:574–577 Sterling TR, Lehmann HP, Frieden TR (2003) Impact of DOTS compared with DOTS-Plus on multidrug resistant tuberculosis and tuberculosis deaths: decision analysis. BMJ 326:574–577
9.
go back to reference World Health Organization (2001) Guidelines for drug susceptibility testing for second line anti-tuberculosis drugs for DOTS-Plus. Document no. WHO/CDS/TB/2001.288. WHO, Geneva, p12 World Health Organization (2001) Guidelines for drug susceptibility testing for second line anti-tuberculosis drugs for DOTS-Plus. Document no. WHO/CDS/TB/2001.288. WHO, Geneva, p12
10.
go back to reference Pfyffer GE, Bonato DA, Ebrahimzadeh A, Gross W, Hotaling J, Kornblum J, Laszlo A, Roberts G, Salinger M, Wittwer F, Siddiqi S (1999) Multicenter laboratory validation of susceptibility testing of Mycobacterium tuberculosis against classical second-line and newer antimicrobial drugs by using the radiometric BACTEC 460 technique and the proportion method with solid media. J Clin Microbiol 37:3179–3186 Pfyffer GE, Bonato DA, Ebrahimzadeh A, Gross W, Hotaling J, Kornblum J, Laszlo A, Roberts G, Salinger M, Wittwer F, Siddiqi S (1999) Multicenter laboratory validation of susceptibility testing of Mycobacterium tuberculosis against classical second-line and newer antimicrobial drugs by using the radiometric BACTEC 460 technique and the proportion method with solid media. J Clin Microbiol 37:3179–3186
11.
go back to reference Inderlied CB, Pfyffer GE (2003) Susceptibility test methods: mycobacteria. In: Murray PR, Baron EJ, Pfaller MA, Jorgensen JH, Yolken RH (eds) Manual of clinical microbiology. American Society for Microbiology, Washington DC, pp1149–1177 Inderlied CB, Pfyffer GE (2003) Susceptibility test methods: mycobacteria. In: Murray PR, Baron EJ, Pfaller MA, Jorgensen JH, Yolken RH (eds) Manual of clinical microbiology. American Society for Microbiology, Washington DC, pp1149–1177
12.
go back to reference Toungoussova OS, Caugant DA, Sandven P, Mariandyshev AO, Bjune G (2002) Drug resistance of Mycobacterium tuberculosis strains isolated from patients with pulmonary tuberculosis in Archangels, Russia. Int J Tuberc Lung Dis 6:406–414 Toungoussova OS, Caugant DA, Sandven P, Mariandyshev AO, Bjune G (2002) Drug resistance of Mycobacterium tuberculosis strains isolated from patients with pulmonary tuberculosis in Archangels, Russia. Int J Tuberc Lung Dis 6:406–414
13.
go back to reference Enarson DA, Rieder HL, Arnadottir T, Trebucq A (1996) Tuberculosis guide for low-income countries. International Union Against Tuberculosis and Lung Diseases, Paris, p65 Enarson DA, Rieder HL, Arnadottir T, Trebucq A (1996) Tuberculosis guide for low-income countries. International Union Against Tuberculosis and Lung Diseases, Paris, p65
14.
go back to reference World Health Organization/International Union Against Tuberculosis and Lung Disease (2001) Revised international definitions in tuberculosis control. Int J Tuberc Lung Dis 5:213–215 World Health Organization/International Union Against Tuberculosis and Lung Disease (2001) Revised international definitions in tuberculosis control. Int J Tuberc Lung Dis 5:213–215
15.
go back to reference Toungoussova OS, Sandven P, Mariandyshev AO, Nizovtseva NI, Bjune G, Caugant DA (2002) Spread of drug-resistant Mycobacterium tuberculosis strains of the Beijing genotype in the Archangel oblast, Russia. J Clin Microbiol 40:1930–1937 Toungoussova OS, Sandven P, Mariandyshev AO, Nizovtseva NI, Bjune G, Caugant DA (2002) Spread of drug-resistant Mycobacterium tuberculosis strains of the Beijing genotype in the Archangel oblast, Russia. J Clin Microbiol 40:1930–1937
16.
go back to reference Siddiqi SH (1995) BACTEC 460 TB System. Product and procedure manual revision. Becton Dickinson Microbiology Systems, Sparks, MD, USA Siddiqi SH (1995) BACTEC 460 TB System. Product and procedure manual revision. Becton Dickinson Microbiology Systems, Sparks, MD, USA
17.
go back to reference Suarez PG, Floyd K, Portocarrero J, Alarcon E, Rapiti E, Ramos G, Bonilla C, Sabogal I, Aranda I, Dye C, Raviglione M, Espinal MA (2002) Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru. Lancet 359:1980–1989 Suarez PG, Floyd K, Portocarrero J, Alarcon E, Rapiti E, Ramos G, Bonilla C, Sabogal I, Aranda I, Dye C, Raviglione M, Espinal MA (2002) Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru. Lancet 359:1980–1989
18.
go back to reference Musser JM (1995) Antimicrobial agent resistance in mycobacteria: molecular genetic insights. Clin Microbiol Rev 8:496–514 Musser JM (1995) Antimicrobial agent resistance in mycobacteria: molecular genetic insights. Clin Microbiol Rev 8:496–514
Metadata
Title
Resistance of multidrug-resistant strains of Mycobacterium tuberculosis from the Archangel oblast, Russia, to second-line anti-tuberculosis drugs
Authors
O. S. Toungoussova
A. O. Mariandyshev
G. Bjune
D. A. Caugant
P. Sandven
Publication date
01-03-2005
Publisher
Springer-Verlag
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 3/2005
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-005-1284-z

Other articles of this Issue 3/2005

European Journal of Clinical Microbiology & Infectious Diseases 3/2005 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine